Monopar Therapeutics Inc. (MNPR) vs Nuvectis Pharma, Inc. (NVCT)
A side-by-side comparison of Monopar Therapeutics Inc. and Nuvectis Pharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MNPR
Monopar Therapeutics Inc.
$78.23HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
NVCT
Nuvectis Pharma, Inc.
$20.88HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
Total return — MNPR vs NVCT
growth of $100 · dividends reinvested · last 5yMNPR +467.3% (+41.5%/yr)NVCT +558.2% (+45.8%/yr)NVCT compounded faster over this window
MNPR NVCT
MNPR vs NVCT: by the numbers
- •NVCT is the larger company ($554M vs $524M market cap).
Metrics side by side
Valuation
| Metric | MNPR | NVCT |
|---|---|---|
| P/B ratio | 4.00 | 61.01 |
Profitability
| Metric | MNPR | NVCT |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -13.64% | -306.61% |
| ROIC | -16.89% | -317.86% |
Growth (annualized)
| Metric | MNPR | NVCT |
|---|---|---|
| Total return CAGR (5Y) | 27.38% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.